Gretel and Illumina Partner to Develop Synthetic Data for Genomic Research

Rhea-AI Summary

Illumina (NASDAQ: ILMN) partners with Gretel.ai to create privacy-protected synthetic genomic data. This collaboration aims to enhance medical research by providing immediate access to statistically accurate genomic datasets without lengthy approval processes. The partnership demonstrates new use cases for synthetic data in genomics, promising advancements in drug discovery and genetic disorder treatment. With a focus on compliance with GDPR and CCPA, this initiative is poised to accelerate DNA sequencing analysis and medical breakthroughs for various health challenges, including COVID-19.

Positive

• Collaboration with Gretel.ai to access privacy-protected synthetic genomic data.
• Potential to accelerate drug discovery and insights into genetic disorders.
• Compliance with major privacy laws (GDPR, CCPA) enhances marketability.
• Immediate access to genomic datasets bypassing lengthy approval processes.

Negative

• None.

The partnership utilizes the highest-quality synthetic data in the market from Gretel to remove privacy bottlenecks and accelerate the development of precision medicine

SAN DIEGO--(BUSINESS WIRE)-- Today, Gretel.ai announced a collaboration with Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, to create privacy-protected, synthetic genomic data that can be accessed by medical researchers anywhere. This announcement includes the release of a successful study the partnership conducted, which proves the viability of significant new use cases for synthetic data in genomics and related fields including medical diagnosis, biotechnology, forensic biology, virology, and biological systematics. Beyond healthcare and life sciences, synthetic data has already proven effective in privacy-related use cases in other industries, such as finance and gaming, to help augment small data collections and balance biased datasets.

This strategic partnership will provide healthcare and life science practitioners access to highly statistically accurate, artificial versions of complex genomic datasets that align with GDPR, CCPA, and other major privacy laws. By using synthetic data, researchers can gain access to datasets immediately and avoid lengthy approval processes by institutional review boards (IRBs) that can take anywhere from 6 months to a year today. “We’re thrilled to show what the highest quality synthetic data available can enable when combined with the groundbreaking genomic work of Illumina’s team,” said Ali Golshan, co-founder and CEO of Gretel.

This privacy-preserving method of sharing sensitive data will also allow a much more accelerated and collaborative approach to next-generation DNA sequencing analysis — leading to the discovery of new drugs, insights into genetic disorders, and disease detection and treatments, which could be used for variants of COVID-19, for example. “This work will inspire new medical discoveries and breakthroughs, and has the potential to help save millions of lives as well as improve the quality of life for generations to come,” said Alex Watson, co-founder and lead Gretel researcher on the partnership study.

You can find more details about the partnership and read the study here.

To get started with Gretel’s synthetic data tools you can sign up here.

About Gretel

Gretel pioneered Privacy Engineering as a Service and a toolkit for synthetic data that features easy-to-use APIs and an open-source AI-based core, built for developers. Companies and developers use Gretel’s APIs to classify and label, transform and anonymize, or create synthetic data to create easy, fast, and safe access to data. Gretel customers use the services either as a SaaS offering or run Gretel’s CLI and APIs in their own environments.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211214006240/en/

Will Jennings

Will@gretel.ai

Source: Gretel

FAQ

What is the partnership between Illumina and Gretel.ai about?

Illumina and Gretel.ai have partnered to create privacy-protected synthetic genomic data to enhance medical research.

How will the Illumina and Gretel partnership impact genomic research?

The partnership aims to accelerate access to genomic datasets, facilitating quicker medical breakthroughs and drug discoveries.

What are the privacy compliance measures taken in the Illumina and Gretel collaboration?

The partnership ensures compliance with GDPR and CCPA, protecting sensitive data while providing access to synthetic genomic datasets.

What are the benefits of using synthetic genomic data in medical research?

Synthetic genomic data allows researchers to bypass lengthy approval processes, enabling faster insights and advancements in healthcare.

When was the Illumina and Gretel partnership announced?

The partnership was announced on December 14, 2021.